Prostate Cancer Screening: A Personal Journey and a Call for Change

Strategic Insights -

As Health Editor of The Telegraph, I recently accompanied my husband Andrew to undergo private prostate screening as part of our campaign coverage. Our experience highlights the importance of targeted screening and the need for better detection methods. Currently, the UK has no national screening system for prostate cancer, and men without symptoms are discouraged from seeking a PSA blood test by their GP. However, demand for private screening has increased since Olympic champion Sir Chris Hoy revealed his terminal diagnosis.

The screening process involved a video consultation, a PSA test by post, and an MRI scan at Vista Health's Waterloo branch. Andrew's PI-RADS score came in at 2-3, indicating an equivocal or intermediate risk of clinically significant cancer. The radiologist found indeterminate signals, denser tissue, and marginal enlargement of the gland, but these signs can also reflect aging, inflammation, or normal variation. Andrew's PSA level was comfortably low at 1.1, but the uncertainty about the results left us feeling uneasy.

We decided to re-review the scans with Prof. Mark Emberton, a leading urologist and pioneer in prostate MRI. After re-assessing the findings, he came to a more reassuring opinion, concluding that Andrew's scan was within the normal range. He recommended an annual PSA test as a baseline for future comparisons and suggested that regular MRI scans for men of a certain age could become the norm.

Our experience has made us more proactive about health and has underlined the need for families to be prepared for the waiting, what-ifs, and quiet reckoning that follows uncertainty. Andrew believes that early detection is crucial for improving chances of a positive outcome, and he supports the use of modern medical tools and advances in techniques to find aggressive cancers earlier and avoid unnecessary treatment.

Key Takeaways:

  • Prostate cancer is the most common cancer among men in the UK, but often comes with no symptoms.
  • Current screening systems are inadequate, and demand for private screening has increased since Sir Chris Hoy's diagnosis.
  • Private screening can provide a baseline for future comparisons, but it is not a substitute for NHS care.
  • Prof. Mark Emberton recommends an annual PSA test as a baseline for future comparisons.
  • Regular MRI scans for men of a certain age could become the norm in the future.
  • The Transform trial will compare different combinations of testing, including MRI scans, genetic risk testing, and PSA blood tests.
  • Early detection of cancer shouldn't be a luxury; it should be how we protect our future.
  • Andrew's experience has made him more proactive about health and highlights the importance of family support during the diagnostic process.

Statistics:

  • 7% of low-risk prostate cancer cases in England are treated with major procedures.
  • Half of prostate cancer cases are diagnosed at later stages, when treatment is less likely to succeed.
  • 10-year survival rate is over 90% for men diagnosed at stages I and II, falling to 18.6% for those with stage IV disease.
  • Vista Health has seen a 152% increase in bookings since Sir Chris Hoy spoke up about his cancer battle.

Sources:

  • The Telegraph
  • Vista Health
  • Prof. Mark Emberton
  • National Prostate Cancer Audit
  • Transform trial
  • UK National Screening Committee